{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:34:07Z","timestamp":1789950847650,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study aimed to evaluate the safety and feasibility of two neoadjuvant chemotherapy (NAC) regimens, gemcitabine plus nab-paclitaxel (GA) and gemcitabine plus S-1 (GS), for elderly patients (aged 75\u00a0years and older) with resectable and borderline resectable pancreatic ductal adenocarcinoma (R\/BR-PDAC). A post hoc analysis was conducted using data from a randomized controlled trial on NAC for R\/BR-PDAC (CSGO-HBP-015). Patients were divided into two groups: those aged 75\u00a0years and older (7\/46 in GS and 16\/48 in GA) and those under 75\u00a0years. Short-term outcomes, including resection rates, adverse events (AEs), postoperative complications, and the administration of adjuvant chemotherapy, were compared between age groups for both regimens. The incidence of AEs in patients aged 75\u00a0years and older tended to be higher than those of younger patients in both chemotherapy arms, but the differences were not statistically significant. However, the resection rates, postoperative complication rates, and the administration of adjuvant chemotherapy were not affected by age. Both regimens showed comparable safety profiles in elderly and younger cohorts. The GA and GS regimens can be safely administered as NAC for R\/BR-PDAC in elderly patients without adversely affecting postoperative outcomes. These findings suggest that both regimens are feasible NAC options even for patients 75\u00a0years and older, supporting the need for further randomized controlled trials to validate these outcomes in the elderly population.<\/jats:p>\n                  <jats:p>\n                    <jats:italic>Trial registration<\/jats:italic>\n                    . UMIN Clinical Trials Registry UMIN000021484. This trial began in April 2016, and first registration (First Posted date) is 01\/04\/2016.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-23185-7","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:17:40Z","timestamp":1762971460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable\/borderline resectable pancreatic adenocarcinoma"],"prefix":"10.1038","volume":"15","clinical-trial-number":[{"clinical-trial-number":"umin000021484","registry":"10.18810\/umin-japan"}],"author":[{"given":"Daisaku","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Iwagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Akita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Asukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terumasa","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigekazu","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Tsujie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadafumi","family":"Asaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osakuni","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Tomokuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"23185_CR1","unstructured":"National Cancer Center J Cancer type statistical information: Pancreas. Cancer information service. (accessed 11 January 2024). https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/cancer\/10_pancreas.html."},{"key":"23185_CR2","unstructured":"International WCRF Pancreatic cancer statistics. (accessed 11 January 2024). https:\/\/www.wcrf.org\/cancer-trends\/pancreatic-cancer-statistics\/."},{"issue":"14","key":"23185_CR3","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle, H. et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310(14), 1473\u20131481. https:\/\/doi.org\/10.1001\/jama.2013.279201 (2013).","journal-title":"JAMA"},{"issue":"10041","key":"23185_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka, K. et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388(10041), 248\u2013257. https:\/\/doi.org\/10.1016\/S0140-6736(16)30583-9 (2016).","journal-title":"Lancet"},{"key":"23185_CR5","doi-asserted-by":"crossref","unstructured":"Unno M. Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP-05). In: Michiaki Unno FMYMSSIMSAHSKWTFHYSTMSHUTK, Tohoku University Graduate School of Medicine SJ, Department of Surgery TUGSoMSJ et al. (eds), Gastrointestinal Cancers Symposium, vol 189. American Society of Clinical Oncology (2019)","DOI":"10.1200\/JCO.2019.37.4_suppl.189"},{"issue":"12","key":"23185_CR6","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1245\/s10434-013-3129-9","volume":"20","author":"F Motoi","year":"2013","unstructured":"Motoi, F. et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol 20(12), 3794\u20133801. https:\/\/doi.org\/10.1245\/s10434-013-3129-9 (2013).","journal-title":"Ann Surg Oncol"},{"key":"23185_CR7","doi-asserted-by":"publisher","first-page":"E193","DOI":"10.2741\/A377","volume":"3","author":"TM Breslin","year":"1998","unstructured":"Breslin, T. M. et al. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Front Biosci 3, E193-203 (1998).","journal-title":"Front Biosci"},{"issue":"5","key":"23185_CR8","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1245\/s10434-011-2110-8","volume":"19","author":"A Andriulli","year":"2012","unstructured":"Andriulli, A. et al. Neoadjuvant\/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 19(5), 1644\u20131662. https:\/\/doi.org\/10.1245\/s10434-011-2110-8 (2012).","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"23185_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jso.23044","volume":"106","author":"KT Papalezova","year":"2012","unstructured":"Papalezova, K. T. et al. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?. J Surg Oncol 106(1), 111\u2013118. https:\/\/doi.org\/10.1002\/jso.23044 (2012).","journal-title":"J Surg Oncol"},{"issue":"5","key":"23185_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12032-017-0951-0","volume":"34","author":"F D'Angelo","year":"2017","unstructured":"D\u2019Angelo, F. et al. Neoadjuvant treatment in pancreatic cancer: Evidence-based medicine? A systematic review and meta-analysis. Med Oncol 34(5), 85. https:\/\/doi.org\/10.1007\/s12032-017-0951-0 (2017).","journal-title":"Med Oncol"},{"issue":"8","key":"23185_CR11","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/bjs.10870","volume":"105","author":"E Versteijne","year":"2018","unstructured":"Versteijne, E. et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg 105(8), 946\u2013958. https:\/\/doi.org\/10.1002\/bjs.10870 (2018).","journal-title":"Br J Surg"},{"key":"23185_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.22.01134","volume":"7","author":"MA Tempero","year":"2022","unstructured":"Tempero, M. A. et al. Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: Results from a randomized, open-label, phase III trial. J Clin Oncol. 7, 1\u20136. https:\/\/doi.org\/10.1200\/JCO.22.01134 (2022).","journal-title":"J Clin Oncol."},{"issue":"18","key":"23185_CR13","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18), 1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369 (2013).","journal-title":"N Engl J Med"},{"issue":"19","key":"23185_CR14","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19), 1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923 (2011).","journal-title":"N Engl J Med"},{"issue":"6","key":"23185_CR15","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00280-018-3577-9","volume":"81","author":"M Ozaka","year":"2018","unstructured":"Ozaka, M. et al. A phase II study of modified FOLFIRINOX for chemotherapy-na\u00efve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 81(6), 1017\u20131023. https:\/\/doi.org\/10.1007\/s00280-018-3577-9 (2018).","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"23185_CR16","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1245\/s10434-024-15199-8","volume":"31","author":"D Yamada","year":"2024","unstructured":"Yamada, D. et al. Results of a randomized clinical study of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (RCT, CSGO-HBP-015). Ann. Surg. Oncol. 31(7), 4621\u20134633 (2024).","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"23185_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/s13063-021-05541-w","volume":"22","author":"D Yamada","year":"2021","unstructured":"Yamada, D. et al. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable\/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS\/GA-rP2, CSGO-HBP-015). Trials 22(1), 568. https:\/\/doi.org\/10.1186\/s13063-021-05541-w (2021).","journal-title":"Trials"},{"issue":"2","key":"23185_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/MPA.0000000000001484","volume":"49","author":"S Kobayashi","year":"2020","unstructured":"Kobayashi, S. et al. A multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer. Pancreas 49(2), 187\u2013192. https:\/\/doi.org\/10.1097\/MPA.0000000000001484 (2020).","journal-title":"Pancreas"},{"issue":"13","key":"23185_CR19","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","volume":"31","author":"H Ueno","year":"2013","unstructured":"Ueno, H. et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31(13), 1640\u20131648. https:\/\/doi.org\/10.1200\/JCO.2012.43.3680 (2013).","journal-title":"J Clin Oncol"},{"issue":"3","key":"23185_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00280-016-2972-3","volume":"77","author":"H Ueno","year":"2016","unstructured":"Ueno, H. et al. Phase I\/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 77(3), 595\u2013603. https:\/\/doi.org\/10.1007\/s00280-016-2972-3 (2016).","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23185-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23185-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23185-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:17:41Z","timestamp":1762971461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23185-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23185"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23185-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39597"}}